Preliminary nod in Japan for Novartis' glycopyrronium for COPD
This article was originally published in Scrip
Executive Summary
Novartis' respiratory portfolio has received a further lift from a positive approval opinion in Japan for Seebri (glycopyrronium bromide (NVA237)), for use in adults with chronic obstructive pulmonary disease (COPD).